---
document_datetime: 2025-12-02 04:52:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/alli.html
document_name: alli.html
version: success
processing_time: 0.1334865
conversion_datetime: 2025-12-24 08:52:30.517526
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Alli (previously Orlistat GSK)

[RSS](/en/individual-human-medicine.xml/66971)

##### Authorised

This medicine is authorised for use in the European Union

orlistat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Alli (previously Orlistat GSK)](#news-on)
- [More information on Alli](#more-information-on-alli-1497)
- [More information on Alli (previously Orlistat GSK)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Alli. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Alli.

Expand section

Collapse section

## What is Alli?

Alli is a medicine that contains the active substance orlistat. It is available as capsules (60 mg) and as chewable tablets (27 mg).

## What is Alli used for?

Alli is used to help patients lose weight. It is used in adults who are overweight with a body mass index (BMI) greater than or equal to 28 kg per square metre, in combination with a low calorie diet with reduced fat levels.

The medicine can be obtained without a prescription.

## How is Alli used?

One Alli capsule or chewable tablet is taken just before, during, or up to one hour after each main meal, three times a day. If a meal is missed or contains no fat, Alli should not be taken. The patient should be on a diet in which about 30% of the calories come from fat. The food in the diet should be spread over three main meals. Alli should not be taken for more than six months.

Patients taking Alli should start a diet and exercise regime before beginning treatment. If patients taking Alli have been unable to lose weight after 12 weeks, they should speak to their doctor or pharmacist. It may be necessary to stop treatment.

## How does Alli work?

The active substance in Alli, orlistat, is an anti-obesity medicine, which does not affect appetite. Orlistat blocks gastrointestinal lipases (enzymes that digest fat). When these enzymes are blocked, they cannot digest some fats in the diet, and this allows about a quarter of the fat eaten in the meal to be passed out in the stools undigested. The body does not absorb this fat and this helps the patient reduce their weight.

## How has Alli been studied?

Because Alli is based on another medicine containing the same active substance already authorised in the European Union (Xenical 120 mg capsules), some of the studies involved patients who took Xenical.

Alli capsules have been studied in three main studies. Two of the studies involving a total of 1,353 overweight or obese patients with a BMI of 28 kg/m 2 or more and lasted from one to two years, comparing Alli given at different doses with placebo (a dummy treatment), in combination with dieting. Neither the patients nor the doctors knew which treatment each patient was taking until the end of the study. The third study compared Alli with placebo in 391 overweight patients with a BMI between 25 and 28 kg/m 2 . The study lasted four months.

In all of the studies, the main measure of effectiveness was the change in weight.

The company also carried out studies to show that Alli 27 mg chewable tablets have the same effect on fat absorption as Alli 60 mg capsules.

## What benefit has Alli shown during the studies?

Alli was more effective than placebo in reducing weight in patients with a BMI of 28 kg/m 2 or more. In the two studies of patients with a BMI of 28 kg/m 2 or more, patients taking Alli 60 mg capsules had lost an average of 4.8 kg after a year, compared with 2.3 kg in those taking placebo.

The study of Alli in patients with a BMI between 25 and 28 kg/m 2 failed to show a degree of weight loss that would be relevant for patients.

The studies comparing the chewable tablets with the capsules showed that the amount of undigested fat passed out in patients' stools was the same after taking either formulation.

## What is the risk associated with Alli?

Most of the side effects with Alli affect the digestive system and are less likely to occur with a low fat diet. In general, they are mild, and occur at the beginning of treatment, going away after some time. The most common side effects with Alli (seen in more than 1 patient in 10) are oily spotting, flatus (gas) with discharge, faecal urgency (urgent need to open the bowels), fatty oily stool, oily evacuation (bowel movements of just oil, without stool), flatulence (gas) and soft stools. For the full list of all side effects reported with Alli, see the package leaflet.

Alli must not be used in people who are hypersensitive (allergic) to orlistat or any of the other ingredients. It must not be used in people who are being treated with ciclosporin (used to prevent organ rejection in transplant patients) or with medicines used to prevent blood clots such as warfarin. It must also not be used in people with chronic malabsorption syndrome (a long-term disease where nutrients from food are not easily absorbed during digestion) or cholestasis (a liver disorder), or in women who are pregnant or breast-feeding.

## Why has Alli been approved?

The CHMP decided that the benefits of Alli are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Alli

The European Commission granted a marketing authorisation valid throughout the EU for Orlistat GSK on 23 July 2007. This authorisation was based on the authorisation already granted in 1998 to Xenical capsules. The name of the medicine was changed to Alli on 12 September 2008.

For more information about treatment with Alli, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Alli : EPAR - Summary for the public

English (EN) (50.5 KB - PDF)

**First published:** 30/04/2009

**Last updated:** 28/11/2012

[View](/en/documents/overview/alli-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-730)

български (BG) (92.15 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/bg/documents/overview/alli-epar-summary-public_bg.pdf)

español (ES) (51.51 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/es/documents/overview/alli-epar-summary-public_es.pdf)

čeština (CS) (140.82 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/cs/documents/overview/alli-epar-summary-public_cs.pdf)

dansk (DA) (111.3 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/da/documents/overview/alli-epar-summary-public_da.pdf)

Deutsch (DE) (74.7 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/de/documents/overview/alli-epar-summary-public_de.pdf)

eesti keel (ET) (51.13 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/et/documents/overview/alli-epar-summary-public_et.pdf)

ελληνικά (EL) (93.97 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/el/documents/overview/alli-epar-summary-public_el.pdf)

français (FR) (51.64 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/fr/documents/overview/alli-epar-summary-public_fr.pdf)

italiano (IT) (112.11 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/it/documents/overview/alli-epar-summary-public_it.pdf)

latviešu valoda (LV) (80.62 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/lv/documents/overview/alli-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (79.12 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/lt/documents/overview/alli-epar-summary-public_lt.pdf)

magyar (HU) (133.87 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/hu/documents/overview/alli-epar-summary-public_hu.pdf)

Malti (MT) (108.94 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/mt/documents/overview/alli-epar-summary-public_mt.pdf)

Nederlands (NL) (51.38 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/nl/documents/overview/alli-epar-summary-public_nl.pdf)

polski (PL) (141.06 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/pl/documents/overview/alli-epar-summary-public_pl.pdf)

português (PT) (111.05 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/pt/documents/overview/alli-epar-summary-public_pt.pdf)

română (RO) (136.92 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/ro/documents/overview/alli-epar-summary-public_ro.pdf)

slovenčina (SK) (138.58 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/sk/documents/overview/alli-epar-summary-public_sk.pdf)

slovenščina (SL) (74.79 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/sl/documents/overview/alli-epar-summary-public_sl.pdf)

Suomi (FI) (112.75 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/fi/documents/overview/alli-epar-summary-public_fi.pdf)

svenska (SV) (111.51 KB - PDF)

**First published:**

30/04/2009

**Last updated:**

28/11/2012

[View](/sv/documents/overview/alli-epar-summary-public_sv.pdf)

Alli : EPAR - Risk-management-plan summary

English (EN) (46.77 KB - PDF)

**First published:** 31/03/2021

[View](/en/documents/rmp-summary/alli-epar-risk-management-plan-summary_en.pdf)

## Product information

Alli : EPAR - Product Information

English (EN) (346.26 KB - PDF)

**First published:** 06/04/2009

**Last updated:** 05/12/2024

[View](/en/documents/product-information/alli-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-920)

български (BG) (444.06 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/bg/documents/product-information/alli-epar-product-information_bg.pdf)

español (ES) (377.42 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/es/documents/product-information/alli-epar-product-information_es.pdf)

čeština (CS) (424.27 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/cs/documents/product-information/alli-epar-product-information_cs.pdf)

dansk (DA) (324.28 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/da/documents/product-information/alli-epar-product-information_da.pdf)

Deutsch (DE) (346.97 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/de/documents/product-information/alli-epar-product-information_de.pdf)

eesti keel (ET) (361.23 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/et/documents/product-information/alli-epar-product-information_et.pdf)

ελληνικά (EL) (491.07 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/el/documents/product-information/alli-epar-product-information_el.pdf)

français (FR) (360.82 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/fr/documents/product-information/alli-epar-product-information_fr.pdf)

hrvatski (HR) (391.58 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/hr/documents/product-information/alli-epar-product-information_hr.pdf)

íslenska (IS) (352.49 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/is/documents/product-information/alli-epar-product-information_is.pdf)

italiano (IT) (352.09 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/it/documents/product-information/alli-epar-product-information_it.pdf)

latviešu valoda (LV) (382.05 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/lv/documents/product-information/alli-epar-product-information_lv.pdf)

lietuvių kalba (LT) (377.38 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/lt/documents/product-information/alli-epar-product-information_lt.pdf)

magyar (HU) (419.48 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/hu/documents/product-information/alli-epar-product-information_hu.pdf)

Malti (MT) (446.69 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/mt/documents/product-information/alli-epar-product-information_mt.pdf)

Nederlands (NL) (386.25 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/nl/documents/product-information/alli-epar-product-information_nl.pdf)

norsk (NO) (300.34 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/no/documents/product-information/alli-epar-product-information_no.pdf)

polski (PL) (397.19 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/pl/documents/product-information/alli-epar-product-information_pl.pdf)

português (PT) (348.68 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/pt/documents/product-information/alli-epar-product-information_pt.pdf)

română (RO) (414.31 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/ro/documents/product-information/alli-epar-product-information_ro.pdf)

slovenčina (SK) (472.15 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/sk/documents/product-information/alli-epar-product-information_sk.pdf)

slovenščina (SL) (423.41 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/sl/documents/product-information/alli-epar-product-information_sl.pdf)

Suomi (FI) (345.32 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/fi/documents/product-information/alli-epar-product-information_fi.pdf)

svenska (SV) (349.8 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

05/12/2024

[View](/sv/documents/product-information/alli-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0074 04/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Alli : EPAR - All Authorised presentations

English (EN) (85.53 KB - PDF)

**First published:** 06/04/2009

**Last updated:** 24/08/2020

[View](/en/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-559)

български (BG) (147.42 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/bg/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_bg.pdf)

español (ES) (103.88 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/es/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_es.pdf)

čeština (CS) (168.37 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/cs/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (105.63 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/da/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (125.73 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/de/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (104.69 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/et/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (168.34 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/el/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_el.pdf)

français (FR) (104.08 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/fr/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (126.65 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/hr/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (104.63 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/is/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_is.pdf)

italiano (IT) (103.94 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/it/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (144.8 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/lv/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (148.77 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/lt/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (148.11 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/hu/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (154.69 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/mt/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (111.33 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/nl/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (104.8 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/no/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_no.pdf)

polski (PL) (149.14 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/pl/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_pl.pdf)

português (PT) (99.22 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/pt/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_pt.pdf)

română (RO) (145.1 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/ro/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (149.98 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/sk/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (104.7 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/sl/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (103.52 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/fi/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (104.93 KB - PDF)

**First published:**

06/04/2009

**Last updated:**

24/08/2020

[View](/sv/documents/all-authorised-presentations/alli-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Alli (previously Orlistat GSK) Active substance orlistat International non-proprietary name (INN) or common name orlistat Therapeutic area (MeSH) Obesity Anatomical therapeutic chemical (ATC) code A08AB01

### Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

### Therapeutic indication

Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m 2 ) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

## Authorisation details

EMA product number EMEA/H/C/000854 Marketing authorisation holder

Haleon Ireland Dungarvan Limited

Knockbrack Dungarvan Co. Waterford IRELAND

Opinion adopted 24/05/2007 Marketing authorisation issued 22/07/2007 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Alli : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (193.07 KB - PDF)

**First published:** 06/04/2009

**Last updated:** 05/12/2024

[View](/en/documents/procedural-steps-after/alli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Alli (previously Orlistat GSK)-SUSA-00002220-201502 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/772580/2015

English (EN) (66.95 KB - PDF)

**First published:** 28/01/2016

**Last updated:** 28/01/2016

[View](/en/documents/scientific-conclusion/alli-previously-orlistat-gsk-susa-00002220-201502-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Alli-H-C-854-A20-0036 : EPAR - Assessment Report

Adopted

Reference Number: EMA/568012/2012

English (EN) (103.66 KB - PDF)

**First published:** 28/11/2012

**Last updated:** 28/11/2012

[View](/en/documents/variation-report/alli-h-c-854-a20-0036-epar-assessment-report_en.pdf)

Alli-H-C-854-A20-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/276569/2012

English (EN) (187.68 KB - PDF)

**First published:** 28/11/2012

**Last updated:** 28/11/2012

[View](/en/documents/variation-report/alli-h-c-854-a20-0029-epar-assessment-report_en.pdf)

Alli-H-C-854-X-0010: EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/547710/2010

English (EN) (422.4 KB - PDF)

**First published:** 20/12/2010

**Last updated:** 20/12/2010

[View](/en/documents/variation-report/alli-h-c-854-x-0010-epar-assessment-report-extension_en.pdf)

Alli-H-C-854-X-0001 : EPAR - Assessment Report - Extension

Reference Number: EMEA/56952/2009

English (EN) (322.74 KB - PDF)

**First published:** 05/02/2009

**Last updated:** 05/02/2009

[View](/en/documents/variation-report/alli-h-c-854-x-0001-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Alli : EPAR - Scientific Discussion

English (EN) (25.12 KB - PDF)

**First published:** 27/07/2007

**Last updated:** 27/07/2007

[View](/en/documents/scientific-discussion/alli-epar-scientific-discussion_en.pdf)

Alli : EPAR - Procedural steps taken before authorisation

English (EN) (160.17 KB - PDF)

**First published:** 27/07/2007

[View](/en/documents/procedural-steps/alli-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Alli (previously Orlistat GSK)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 July 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-july-2012) 20/07/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines](/en/news/european-medicines-agency-confirms-positive-benefit-risk-balance-orlistat-containing-medicines) 16/02/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-september-2011) 23/09/2011

[European Medicines Agency starts review of orlistat-containing medicines](/en/news/european-medicines-agency-starts-review-orlistat-containing-medicines) 22/09/2011

[European Medicines Agency recommends first switch from prescription-only to non-prescription for a centrally authorised medicine](/en/news/european-medicines-agency-recommends-first-switch-prescription-only-non-prescription-centrally-authorised-medicine) 23/10/2008

#### More information on Alli

Questions and answers on the review of centrally authorised medicines with ingredients manufactured at Roche Carolina Inc., Florence, United States

Reference Number: EMA/476366/2012

English (EN) (81.91 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-centrally-authorised-medicines-ingredients-manufactured-roche-carolina-inc-florence-united-states_en.pdf)

Questions and answers on the review of orlistat-containing medicines

Adopted

Reference Number: EMA/CHMP/113837/2012 Rev.1

English (EN) (80.64 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 21/12/2012

[View](/en/documents/referral/questions-and-answers-review-orlistat-containing-medicines_en.pdf)

[Other languages (21)](#file-language-dropdown-240)

български (BG) (118.59 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/bg/documents/referral/questions-and-answers-review-orlistat-containing-medicines_bg.pdf)

español (ES) (99.92 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/es/documents/referral/questions-and-answers-review-orlistat-containing-medicines_es.pdf)

čeština (CS) (123.82 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/cs/documents/referral/questions-and-answers-review-orlistat-containing-medicines_cs.pdf)

dansk (DA) (95.06 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/da/documents/referral/questions-and-answers-review-orlistat-containing-medicines_da.pdf)

Deutsch (DE) (98.67 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/de/documents/referral/questions-and-answers-review-orlistat-containing-medicines_de.pdf)

eesti keel (ET) (121.07 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/et/documents/referral/questions-and-answers-review-orlistat-containing-medicines_et.pdf)

ελληνικά (EL) (126.31 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/el/documents/referral/questions-and-answers-review-orlistat-containing-medicines_el.pdf)

français (FR) (99.07 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/fr/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fr.pdf)

italiano (IT) (117.49 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/it/documents/referral/questions-and-answers-review-orlistat-containing-medicines_it.pdf)

latviešu valoda (LV) (120.32 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/lv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lv.pdf)

lietuvių kalba (LT) (120.89 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/lt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lt.pdf)

magyar (HU) (113.19 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/hu/documents/referral/questions-and-answers-review-orlistat-containing-medicines_hu.pdf)

Malti (MT) (122.96 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/mt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_mt.pdf)

Nederlands (NL) (95.18 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/nl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_nl.pdf)

polski (PL) (112.17 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/pl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pl.pdf)

português (PT) (86.42 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/pt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pt.pdf)

română (RO) (113.38 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/ro/documents/referral/questions-and-answers-review-orlistat-containing-medicines_ro.pdf)

slovenčina (SK) (112.48 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sk/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sk.pdf)

slovenščina (SL) (108.67 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sl.pdf)

Suomi (FI) (95.69 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/fi/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fi.pdf)

svenska (SV) (86.83 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sv.pdf)

#### More information on Alli (previously Orlistat GSK)

- [Evaluating the effectiveness of the revised alli® pack information in helping pharmacy staff within the EU supply alli® appropriately (204675) - post-authorisation study](https://catalogues.ema.europa.eu/study/28353)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/12/2024

## Share this page

[Back to top](#main-content)